300723 一品红
已收盘 05-22 15:00:00
资讯
新帖
简况
一品红最新公告:全资子公司获氨基己酸注射液注册证书
证券之星 · 05-21 18:40
一品红最新公告:全资子公司获氨基己酸注射液注册证书
股市必读:一品红(300723)5月20日董秘有最新回复
证券之星 · 05-21 01:12
股市必读:一品红(300723)5月20日董秘有最新回复
一品红:氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组
证券之星 · 05-20
一品红:氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组
一品红:公司正在有序规划及准备AR882后续上市后的商业化事宜
证券之星 · 05-20
一品红:公司正在有序规划及准备AR882后续上市后的商业化事宜
一品红:AR882正在进行关键性Ⅲ期临床试验
证券之星 · 05-20
一品红:AR882正在进行关键性Ⅲ期临床试验
一品红:2024年8月AR882被美国FDA授予快速通道资格
证券之星 · 05-19
一品红:2024年8月AR882被美国FDA授予快速通道资格
一品红:坚持以儿童临床需求为导向
证券之星 · 05-19
一品红:坚持以儿童临床需求为导向
一品红:降尿酸及痛风药市场未来十分可期
证券之星 · 05-19
一品红:降尿酸及痛风药市场未来十分可期
一品红:相关政策的出台为行业企业的发展带来了积极影响
证券之星 · 05-19
一品红:相关政策的出台为行业企业的发展带来了积极影响
一品红:AR882正在进行关键性Ⅲ期临床试验
证券之星 · 05-19
一品红:AR882正在进行关键性Ⅲ期临床试验
一品红(300723)披露2025年度股东会法律意见书,5月18日股价下跌3.34%
证券之星 · 05-18
一品红(300723)披露2025年度股东会法律意见书,5月18日股价下跌3.34%
一品红:公司在研的创新药氘泊替诺雷(AR882)是一种高效选择性尿酸转运蛋白(URAT1)抑制剂,用于降低血尿酸治疗痛风及溶解痛风石
证券之星 · 05-12
一品红:公司在研的创新药氘泊替诺雷(AR882)是一种高效选择性尿酸转运蛋白(URAT1)抑制剂,用于降低血尿酸治疗痛风及溶解痛风石
一品红:截止至2026年4月30日,公司股东总户数41,977户
证券之星 · 05-08
一品红:截止至2026年4月30日,公司股东总户数41,977户
一品红:氘泊替诺雷全球Ⅲ期临床完成全部受试者入组
证券之星 · 04-30
一品红:氘泊替诺雷全球Ⅲ期临床完成全部受试者入组
30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧
一品红(300723)3月31日股东户数3.08万户,较上期增加6.05%
证券之星 · 04-24
一品红(300723)3月31日股东户数3.08万户,较上期增加6.05%
图解一品红一季报:第一季度单季净利润同比增长950.35%
证券之星 · 04-24
图解一品红一季报:第一季度单季净利润同比增长950.35%
一品红(300723.SZ)发布一季度业绩,归母净利润5.94亿元,增长950.35%
智通财经 · 04-24
一品红(300723.SZ)发布一季度业绩,归母净利润5.94亿元,增长950.35%
一品红最新公告:全资子公司获得卡络磺钠注射液注册证书
证券之星 · 04-10
一品红最新公告:全资子公司获得卡络磺钠注射液注册证书
一品红:并购协议已满足所有交割条件,协议已正式生效
证券之星 · 04-08
一品红:并购协议已满足所有交割条件,协议已正式生效
暂无数据
公司概况
公司名称:
一品红药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2017-11-16
主营业务:
一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。
发行价格:
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":41.06,"timestamp":1779433398000,"preClose":39.8,"halted":0,"volume":18859753,"delay":0,"changeRate":0.0317,"floatShares":419000000,"shares":451999999,"eps":0.4428,"marketStatus":"已收盘","change":1.26,"latestTime":"05-22 15:00:00","open":39.67,"high":41.36,"low":39.08,"amount":766000000,"amplitude":0.0573,"askPrice":41.07,"askSize":6,"bidPrice":41.06,"bidSize":260,"shortable":0,"etf":0,"ttmEps":0.4428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779672600000},"marketStatusCode":5,"adr":0,"adjPreClose":39.8,"symbolType":"stock","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":43.78,"lowLimit":35.82,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":9.29,"roa":"--","peRate":92.728094,"roe":"35.91%","epsLYR":-0.7478,"committee":0.623661,"marketValue":18547000000,"turnoverRate":0.045,"status":0,"floatMarketCap":17212000000},"requestUrl":"/m/hq/s/300723/tweets","defaultTab":"tweets","newsList":[{"id":"2637387542","title":"一品红最新公告:全资子公司获氨基己酸注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637387542?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:40","pubTimestamp":1779360004,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称,全资子公司广州一品红制药近日收到国家药监局核准签发的氨基己酸注射液《药品注册证书》,该药品为化学药品3类,视同通过一致性评价,用于预防及治疗血纤维蛋白溶解亢进引起的各种出血。2025年该药品在中国城市和县级公立医院销售规模约7388万元。此次获批将进一步丰富公司产品管线,增强核心竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637243048","title":"股市必读:一品红(300723)5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637243048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637243048?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:12","pubTimestamp":1779297131,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,一品红报收于38.18元,下跌0.78%,换手率2.27%,成交量9.51万手,成交额3.63亿元。董秘最新回复投资者: 公司是否已经开始组建 AR882 的商业化团队?2025年8月,公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组;2025年11月,AR882国内Ⅲ期临床试验完成全部患者入组。公司将严格按照相关法律法规要求履行信息披露义务。当日关注点来自交易信息汇总:5月20日主力资金净流出3558.94万元,散户资金净流入3737.08万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100001746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817159","title":"一品红:氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636817159?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267637,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红05月20日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问AR882氘泊替诺雷国内三期临床是否按计划6月完成收尾?2025年8月,公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组;2025年11月,AR882国内Ⅲ期临床试验完成全部患者入组。目前,AR882正在进行关键性Ⅲ期临床试验,相关试验开展顺利,产品上市时间可期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636175108","title":"一品红:公司正在有序规划及准备AR882后续上市后的商业化事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2636175108","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636175108?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:57","pubTimestamp":1779267434,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问:公司是否已经开始组建 AR882 的商业化团队?团队规模和人员构成是怎样的?一品红回复:尊敬的投资者您好,感谢您对公司的关注。公司正在有序规划及准备AR882后续上市后的商业化事宜,公司会制定切实可行的完整的商业化市场方案,在产品上市前逐步调整到位。药品研发具有周期长、投入高、风险大等特点,敬请广大投资者谨慎决策,注意投资风险。祝您投资愉快。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814889","title":"一品红:AR882正在进行关键性Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814889?lang=zh_cn&edition=full","pubTime":"2026-05-20 15:57","pubTimestamp":1779263825,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红05月20日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,AR882的R2预计在q2发布,近期公司股价持续走低,请问公司数据是否存在泄露情况,如信立泰一样,结果不及预期一品红回复:尊敬的投资者您好,感谢您对公司的关注。股价波动受资本市场环境、公司经营等多种综合因素的影响。目前,AR882正在进行关键性Ⅲ期临床试验,试验进展顺利。公司将严格按照相关法律法规要求履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000026316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636859150","title":"一品红:2024年8月AR882被美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2636859150","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636859150?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:52","pubTimestamp":1779195159,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红05月19日在投资者关系平台上答复投资者关心的问题。请问这对其在美国的上市进程有何帮助?2024年 8 月 AR882 被美国 FDA 授予快速通道资格认定。这一认定适用于AR882在治疗临床痛风患者可见痛风石方面的应用,是AR882研发历程中的重要里程碑,将有助于加速推进该药的临床试验和注册上市进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900041284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833871","title":"一品红:坚持以儿童临床需求为导向","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833871?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175103,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问:儿童药的研发难度大、周期长,公司如何保持在儿童药领域的研发优势?一品红回复:尊敬的投资者您好,感谢您对公司的关注。公司坚持以儿童临床需求为导向,采取自主研发与合作开发等模式相结合,致力于儿童用药的全面技术创新,以提高儿童专用制剂的研发水平,研制口感佳、安全性高、剂量精准的儿童药物,重点解决儿童用药依从性差、安全隐患多等临床难题。祝您投资愉快。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833847","title":"一品红:降尿酸及痛风药市场未来十分可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833847?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175102,"startTime":"0","endTime":"0","summary":"据《中国高尿酸血症与痛风诊疗指南》,中国高尿酸血症的总体患病率为13.3%,痛风总体发病率为1.1%。根据弗若斯特沙利文预测,中国高尿酸血症患者人数从2019年的1.83亿人增至2024年的2.21亿人,年复合年增长率为3.8%,且预计到2033年将达2.86亿人,2024年至2033年的年复合增长率2.9%。降尿酸及痛风药市场未来十分可期。此外,药品获批上市后的生产和销售将受到市场、环境变化等不确定因素影响,存在销售不达预期的风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636338468","title":"一品红:相关政策的出台为行业企业的发展带来了积极影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2636338468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636338468?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175102,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问:国家出台了多项支持儿童药发展的政策,请问这些政策对公司的儿童药业务有何积极影响?一品红回复:尊敬的投资者您好,感谢您对公司的关注。国家相关部门始终高度重视儿童药品的发展。涵盖儿童用药保障需求、鼓励研发、优先审评、简化采购程序、扩大医保支付范围等多个方面。相关政策的出台为行业企业的发展带来了积极影响。祝您投资愉快。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833843","title":"一品红:AR882正在进行关键性Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833843?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:15","pubTimestamp":1779174919,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问:AR882 的成功研发对公司从传统仿制药企向创新药企转型具有怎样的里程碑意义?一品红回复:尊敬的投资者您好,感谢您对公司的关注。目前,AR882正在进行关键性Ⅲ期临床试验,尚处于临床研究阶段。祝您投资愉快。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071100","title":"一品红(300723)披露2025年度股东会法律意见书,5月18日股价下跌3.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071100?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:04","pubTimestamp":1779113096,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘,一品红报收于38.75元,较前一交易日下跌3.34%,最新总市值为175.03亿元。近日,一品红药业集团股份有限公司披露北京市中伦(广州)律师事务所出具的《关于一品红药业集团股份有限公司2025年度股东会的法律意见书》。法律意见书指出,本次股东会的召集、召开程序、出席人员资格、表决程序及表决结果均符合相关法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800036955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634268476","title":"一品红:公司在研的创新药氘泊替诺雷(AR882)是一种高效选择性尿酸转运蛋白(URAT1)抑制剂,用于降低血尿酸治疗痛风及溶解痛风石","url":"https://stock-news.laohu8.com/highlight/detail?id=2634268476","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634268476?lang=zh_cn&edition=full","pubTime":"2026-05-12 11:33","pubTimestamp":1778556808,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月11日在投资者关系平台上答复投资者关心的问题。投资者提问:5月15日,ASCO会摘录贵公司疼风药第三期临床结果吗一品红回复:尊敬的投资者您好,感谢您对公司的关注。ASCO是临床肿瘤学领域的学术会议。公司在研的创新药氘泊替诺雷(AR882)是一种高效选择性尿酸转运蛋白(URAT1)抑制剂,用于降低血尿酸治疗痛风及溶解痛风石。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200016638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK0239","BK1574","300723","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633884764","title":"一品红:截止至2026年4月30日,公司股东总户数41,977户","url":"https://stock-news.laohu8.com/highlight/detail?id=2633884764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633884764?lang=zh_cn&edition=full","pubTime":"2026-05-08 11:34","pubTimestamp":1778211280,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截至4月30日公司的股东人数是多少?谢谢一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年4月30日,公司股东总户数41,977户。祝您投资愉快。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800017190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631074579","title":"一品红:氘泊替诺雷全球Ⅲ期临床完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2631074579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631074579?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:09","pubTimestamp":1777511344,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红04月29日在投资者关系平台上答复投资者关心的问题。2025年8月,公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组;2025年11月,AR882国内Ⅲ期临床试验完成全部患者入组。目前, AR882正在进行关键性Ⅲ期临床试验,产品上市时间可期。公司将全力推动AR882在中国地区的临床研发及后续商业化事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000030929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日,A股医药板块迎来一季度财报密集披露期,包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","301281","06978","BK0183","000963","688117","BK0209","300723","BK0071","600216","BK1161","000950","BK1574","BK0216","BK0239","BK0250","BK0188","BK0191","688621","LU2328871848.SGD","002550","BK0187","BK0196","BK0028","LU1969619763.USD","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814054","title":"一品红(300723)3月31日股东户数3.08万户,较上期增加6.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814054","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814054?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:40","pubTimestamp":1777023653,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年3月31日公司股东户数为3.08万户,较2月28日增加1757.0户,增幅为6.05%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.51万户。从股价来看,2026年2月28日至2026年3月31日,一品红区间跌幅为2.17%,在此期间股东户数增加1757.0户,增幅为6.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852958","title":"图解一品红一季报:第一季度单季净利润同比增长950.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852958?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:37","pubTimestamp":1776969422,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红2026年一季报显示,一季度公司主营收入3.85亿元,同比上升2.26%;归母净利润5.94亿元,同比上升950.35%;扣非净利润-269.32万元,同比下降117.73%;负债率58.04%,投资收益5.82亿元,财务费用1308.07万元,毛利率66.08%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400006519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629596548","title":"一品红(300723.SZ)发布一季度业绩,归母净利润5.94亿元,增长950.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629596548","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629596548?lang=zh_cn&edition=full","pubTime":"2026-04-24 00:15","pubTimestamp":1776960923,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)发布2026年第一季度报告,该公司营业收入为3.85亿元,同比增长2.26%。归属于上市公司股东的净利润为5.94亿元,同比增长950.35%。归属于上市公司股东的扣除非经常性损益的净亏损为269.32万元。基本每股收益为1.3159元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"一品红(300723.SZ)发布一季度业绩,归母净利润5.94亿元,增长950.35%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626419363","title":"一品红最新公告:全资子公司获得卡络磺钠注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626419363","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626419363?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:02","pubTimestamp":1775811776,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称,公司全资子公司广州一品红制药有限公司于近日收到国家药监局核准签发的卡络磺钠注射液《药品注册证书》。该药品为化学药品3类,视同通过一致性评价,属于国家医保乙类产品,主要用于泌尿系统、上消化道等出血疾病的治疗。根据米内网数据,2025年卡络磺钠在中国城市和县级公立医院的销售规模约为3.27亿元。此次获得注册证书标志着公司具备了在国内市场销售该规格药品的资格,将进一步丰富公司产品管线和品类,增强公司竞争力。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000028483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994143","title":"一品红:并购协议已满足所有交割条件,协议已正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994143","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625994143?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:51","pubTimestamp":1775652665,"startTime":"0","endTime":"0","summary":"2025年12月,公司参股公司美国Arthrosi与Sobi美国签署并购协议,Sobi美国以9.5亿美元首付款,以及最高达5.5亿美元的临床、注册和销售里程碑付款收购Arthrosi 100%股权。目前,并购协议已满足所有交割条件,协议已正式生效。公司子公司瑞腾生物(香港)有限公司已收到 Arthrosi首期并购款11,915.89万美元。公司将根据相关规定,就出售参股公司股权事项的后续进展及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800036372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779549024463,"stockEarnings":[{"period":"1week","weight":0.0242},{"period":"1month","weight":0.1511},{"period":"3month","weight":0.2334},{"period":"6month","weight":-0.1524},{"period":"1year","weight":-0.135},{"period":"ytd","weight":0.2238}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0076},{"period":"6month","weight":0.0725},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41977人(较上一季度增加36.27%)","perCapita":"9986股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}